Skip to main content
. 2015 Aug 12;89(20):10637–10647. doi: 10.1128/JVI.01868-15

FIG 7.

FIG 7

Mice surviving the initial CT-2A-Fluc inoculation become resistant to tumor rechallenge. (A) Mice imaged with the IVIS system after CT-2A-Fluc rechallenge. (B) C57BL/6 mouse tumor cell-reactive antibodies detected with immunofluorescence from sera of rechallenged mice. Blue, cell nuclei (stained with DAPI); red, tumor cell-reactive antibodies.